EUS-Guided Choledochoduodenostomy Versus ERCP for Primary Biliary Decompression in Distal Malignant Biliary Obstruction

  • days left to enroll
  • participants needed
  • sponsor
    Mansoura University
Updated on 26 September 2021


Malignant biliary obstruction commonly caused by pancreatic adenocarcinoma, cholangiocarcinoma and other etiologies like gallbladder carcinoma, hepatocellular carcinoma, lymphoma, and metastasis to regional solid organs and lymph nodes.

Pancreatobiliary cancers generally present with jaundice, weight loss, and anorexia with significant impact on quality of life, morbidity, and mortality.

The primary goal of diagnosis and management is curative resection but it's difficult due to local invasion and distant metastases at the time of clinical presentation. Biliary decompression helps to reduce symptoms and improve quality of life in patients with malignant biliary obstruction.

Endoscopically placed stents have become the standard of care for non-surgical biliary drainage due to their minimal invasiveness compared to percutaneous drainage.

The standard treatment of obstructive jaundice has been ERCP with biliary stent placement with high success rate in expert hands and low frequency of adverse events.

Endoscopic ultrasound-guided biliary drainage (EUS-BD) has been increasingly used in patients who underwent failed ERCP. EUS-BD can be performed in several ways, choledochoduodenostomy (CDS), hepaticogastrostomy (HGS), antegrade (AG) procedure, and rendezvous (RV) technique.


This study will be a single center, prospective randomized comparative study that includes 50 patients with distal malignant biliary obstruction including pancreatic head masses, distal cholangiocarcinoma or papillary carcinoma.

All patients with inclusion criteria will be recruited in the study by simple random sampling using sealed envelopes until fulfillment of needed sample size for both EUS-BD arm and ERCP-BD arm.

Study tools:

  • Informed consent will be obtained from each participant sharing in the study.
  • Throughout history taking, complete general examination and local abdominal examination.
  • Laboratory investigations: CBC, Serum creatinine, Liver functions tests (AST, ALT and Serum Albumin), Alkaline phosphatase, Serum bilirubin and INR.
  • ERCP-BD by papillary approach and EUS-BD by choledochoduodenostomy with transmural stent placement.
  • All procedures will be performed under deep sedation or general anesthesia in the left lateral position.
  • Procedural time is recorded.
  • Technical success is considered after stent placement (expanded and patent) with good bile flow and drainage.
  • Follow up:
  • Lab investigations will be requested at 2 days, 2 and 4 weeks, 3 and 6 months after the procedure including:

CBC, S.Cr, S.Bil, AST, ALT, S.Alb, ALP and INR.

  • Early adverse events (within 48 hours after procedure) including: Pancreatitis, Cholangitis, Bleeding, Perforation and Peritonitis.
  • Late adverse events include stent dysfunction either due to food impaction, tumor ingrowth or stent migration.
  • Clinical success is considered at 2 weeks if total bilirubin is less than 50% of baseline and at 4 weeks if total bilirubin is less than 3mg/dL.

Condition Malignant Biliary Obstruction
Treatment Biliary drainage
Clinical Study IdentifierNCT04898777
SponsorMansoura University
Last Modified on26 September 2021


Yes No Not Sure

Inclusion Criteria

Age: 18 years and older
Presence of locally advanced or metastatic pancreatic head mass on CT or magnetic resonance imaging of the abdomen
Absence of duodenal obstruction
Elevated liver tests with serum bilirubin at least 3 times above the upper limit of normal (1.2 mg/dL)
Histologic or cytologic diagnosis of malignancy
Accept sharing in the study

Exclusion Criteria

Age younger than 18 years
Hilar biliary obstruction (as the main lesion or coexisting with distal obstruction)
Presence of duodenal obstruction
Histologic or cytologic diagnosis of malignancy
Patients underwent previous intervention for biliary drainage
Previously failed biliary cannulation at ERCP
Prior biliary sphincterotomy or stent placement
Surgically altered anatomy or inability to access the major duodenal papilla
Patients unfit for anesthesia
Patients having uncorrectable coagulopathy or thrombocytopenia
History of allergy to radiocontrast agents
Refuse sharing in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note